Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3134]

ASH 2021: Bispecific antibody mosunetuzumab brings deep remission for follicular lymphoma

ASH 2021: Bispecific antibody mosunetuzumab brings deep remission for follicular lymphoma

ASH 2021: Axicabtagene ciloleucel shows durable responses after two years for patients with indolent non-Hodgkin lymphoma

ASH 2021: Axicabtagene ciloleucel shows durable responses after two years for patients with indolent non-Hodgkin...

ASH 2021: Axicabtagene ciloleucel demonstrates potential as first-line therapy for patients with high-risk large B-cell lymphoma

ASH 2021: Axicabtagene ciloleucel demonstrates potential as first-line therapy for patients with high-risk large B...

$ASH 2021: TRANSFORM study reports CAR T-cell therapy liso-cel significantly improves outcomes for relapsed and refractory large B-cell lymphoma$

ASH 2021: TRANSFORM study reports CAR T-cell therapy liso-cel significantly improves outcomes for relapsed and...

ASH 2021: Immune-boosting antibody treatment isatuximab meets primary endpoint for multiple myeloma

ASH 2021: Immune-boosting antibody treatment isatuximab meets primary endpoint for multiple myeloma

ASH 2021: ZUMA-7 demonstrates lasting benefits of CAR-T therapy over current standard of care for large B-cell lymphoma

ASH 2021: ZUMA-7 demonstrates lasting benefits of CAR-T therapy over current standard of care for large B-cell...

ASH 2021: Study suggests need for earlier conversations about end-of-life decisions for patients with high-risk acute myeloid leukaemia

ASH 2021: Study suggests need for earlier conversations about end-of-life decisions for patients with high-risk...

ASH 2021: Persistent racial disparities in acute lymphoblastic leukaemia survival

ASH 2021: Persistent racial disparities in acute lymphoblastic leukaemia survival

ASH 2021: Ivosidenib combined with azacitidine improves outcomes for newly diagnosed acute myeloid leukaemia with IDH-1 mutation compared with azacitidine alone

ASH 2021: Ivosidenib combined with azacitidine improves outcomes for newly diagnosed acute myeloid leukaemia with...

Moderate immune response is more effective against leukaemia

Moderate immune response is more effective against leukaemia

More from ecancer